These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 31888300)

  • 21. Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience.
    Palmer M; Maynard OM
    Harm Reduct J; 2022 Jul; 19(1):81. PubMed ID: 35871679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world.
    Watts R; Kettner H; Geerts D; Gandy S; Kartner L; Mertens L; Timmermann C; Nour MM; Kaelen M; Nutt D; Carhart-Harris R; Roseman L
    Psychopharmacology (Berl); 2022 Nov; 239(11):3461-3483. PubMed ID: 35939083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternative beliefs in psychedelic drug users.
    Lebedev AV; Acar K; Horntvedt O; Cabrera AE; Simonsson O; Osika W; Ingvar M; Petrovic P
    Sci Rep; 2023 Sep; 13(1):16432. PubMed ID: 37777572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: a large, international, self-selecting online survey.
    Lawn W; Hallak JE; Crippa JA; Dos Santos R; Porffy L; Barratt MJ; Ferris JA; Winstock AR; Morgan CJA
    Sci Rep; 2017 Nov; 7(1):15201. PubMed ID: 29123145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences.
    Orłowski P; Ruban A; Szczypiński J; Hobot J; Bielecki M; Bola M
    J Psychopharmacol; 2022 Aug; 36(8):987-1000. PubMed ID: 35475373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting Responses to Psychedelics: A Prospective Study.
    Haijen ECHM; Kaelen M; Roseman L; Timmermann C; Kettner H; Russ S; Nutt D; Daws RE; Hampshire ADG; Lorenz R; Carhart-Harris RL
    Front Pharmacol; 2018; 9():897. PubMed ID: 30450045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychedelic drug use and schizotypy in young adults.
    Lebedev AV; Acar K; Garzón B; Almeida R; Råback J; Åberg A; Martinsson S; Olsson A; Louzolo A; Pärnamets P; Lövden M; Atlas L; Ingvar M; Petrovic P
    Sci Rep; 2021 Jul; 11(1):15058. PubMed ID: 34301969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Ayahuasca on Gratitude and Relationships with Nature: A Prospective, Naturalistic Study.
    Aday JS; Bloesch EK; Davis AK; Domoff SE; Scherr K; Woolley JD; Davoli CC
    J Psychoactive Drugs; 2024 Feb; ():1-10. PubMed ID: 38310541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder.
    Spriggs MJ; Kettner H; Carhart-Harris RL
    Eat Weight Disord; 2021 May; 26(4):1265-1270. PubMed ID: 32895801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychedelic use and intimate partner violence: The role of emotion regulation.
    Thiessen MS; Walsh Z; Bird BM; Lafrance A
    J Psychopharmacol; 2018 Jul; 32(7):749-755. PubMed ID: 29807492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A unified model of ketamine's dissociative and psychedelic properties.
    Marguilho M; Figueiredo I; Castro-Rodrigues P
    J Psychopharmacol; 2023 Jan; 37(1):14-32. PubMed ID: 36527355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders.
    Lea T; Amada N; Jungaberle H; Schecke H; Scherbaum N; Klein M
    Psychopharmacology (Berl); 2020 May; 237(5):1521-1532. PubMed ID: 32043165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The association of psychedelic use and opioid use disorders among illicit users in the United States.
    Pisano VD; Putnam NP; Kramer HM; Franciotti KJ; Halpern JH; Holden SC
    J Psychopharmacol; 2017 May; 31(5):606-613. PubMed ID: 28196428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Broadening Your Mind to Include Others: The relationship between serotonergic psychedelic experiences and maladaptive narcissism.
    van Mulukom V; Patterson RE; van Elk M
    Psychopharmacology (Berl); 2020 Sep; 237(9):2725-2737. PubMed ID: 32472162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What Predicts Beneficial Outcomes in Psychedelic Use? A Quantitative Content Analysis of Psychedelic Health Outcomes.
    Acevedo EC; Uhler S; White KP; Al-Shawaf L
    J Psychoactive Drugs; 2024 Feb; ():1-10. PubMed ID: 38341606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience.
    Peill JM; Trinci KE; Kettner H; Mertens LJ; Roseman L; Timmermann C; Rosas FE; Lyons T; Carhart-Harris RL
    J Psychopharmacol; 2022 Jan; 36(1):31-45. PubMed ID: 34983255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychedelics not linked to mental health problems or suicidal behavior: a population study.
    Johansen PØ; Krebs TS
    J Psychopharmacol; 2015 Mar; 29(3):270-9. PubMed ID: 25744618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of the Japanese version of the Ego-Dissolution Inventory (EDI).
    Kusudo K; Tani H; Yonezawa K; Nakajima S; Nour MM; Carhart-Harris R; Uchida H
    Neuropsychopharmacol Rep; 2024 Mar; 44(1):292-297. PubMed ID: 38318991
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.